Copper Intrauterine Devices Tied to Lower Risk for Cervical Cancer
Findings based on comparison to hormonal intrauterine devices.
Findings based on comparison to hormonal intrauterine devices.
The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass index (BMI) <30kg/m2 for whom a combined hormonal contraceptive is appropriate.
Compared to nonhormonal contraception, hormonal contraception appears to pose a greater risk for increased seizure frequency in women with epilepsy.
Symptoms of depression are associated with oral contraceptive use in 16-year-old girls compared with adolescents and young women up to 25 years of age.
Adherence to guidelines high for patients with medical contraindications to oral contraceptives.
Over-the-counter hormonal contraception access recommended with no age restrictions.
Findings show long-term impact, regardless of current oral contraception use in adulthood.
Jubilant Cadista Pharmaceuticals is recalling 1 lot of the combination oral contraceptive Drospirenone and Ethinyl Estradiol Tablets, USP, 3mg/0.02mg due to the possibility of decreased product efficacy.
No significant difference seen with use of DMPA-IM, copper IUD device, levonorgestrel implant in African women.
Risk for acute cruciate ligament reconstruction reduced while on OCP, especially for 15- to 19-year-olds.